Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.

The effectiveness of antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia (ET) is not proven. In this study, the incidence rates of arterial and venous thrombosis were retrospectively analyzed in 300 low-risk patients with ET treated with antiplatelet drugs as monotherapy (n = 198) or followed with careful observation (n = 102). Follow-up was 802 and 848 person-years for antiplatelet therapy and observation, respectively.

[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia].

Background And Objective: A retrospective analysis of a registration database was used to assess the efficacy and tolerability of anagrelide for treating essential thrombocythemia (ET). The study was conducted by analysing information on response to treatment, time to response and tolerability.

Patients And Method: A total of 411 patients with ET from 54 centres in Spain were included in a retrospective chart review.

CD45RA+ and CD45RO+ lymphocyte subpopulations in patients with monoclonal gammopathies: correlations with diagnosis, clinical stage and treatment status.

Alterations in blood lymphocyte subsets may be involved in the development of overt myeloma. Naive (CD4+CD45RA+) and memory (CD4+CD45RO+) helper T-cell subsets are important effectors of immune T-cell regulation. We analyzed the distribution of these blood lymphocyte subpopulations in patients with monoclonal gammopathies, considering the type of disorder, clinical stage, and treatment status.